The evidence points to a clear investment proposition for Eli Lilly: the company is at the forefront of a rapidly expanding GLP-1 market, but its next phase of growth will depend on defending tirzepatide’s leadership while advancing differentiated oral and next-generation therapies. Tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, is a dual GLP-1/GIP agonist 9,25,28,30. It is described as the world’s best-selling drug 24, and its trailing sales have surpassed Novo Nordisk’s Ozempic by a meaningful margin; in 2025, Mounjaro’s trailing-twelve-month sales were approximately 1.7 times those of Ozempic 8.
The opportunity remains substantial. Global GLP-1 use is expected to increase from approximately 20 million patients at the end of the prior year to 30 million by the end of 2026 27, while broader reimbursement and access could expand the treated population further 34. Yet the formulation is becoming more crowded. Price pressure, reimbursement uncertainty, litigation exposure, and a widening pipeline of oral, dual-agonist, triple-agonist, and longer-acting therapies will determine whether market expansion translates into durable share, pricing power, and cash-flow growth.
Scientific Foundation: Tirzepatide Remains the Commercial Anchor
The strongest evidence concerns tirzepatide’s current clinical and commercial position. Multiple claims identify Mounjaro as a leading or dominant product in the GLP-1 and incretin market 8,33,40. In the SURMOUNT-1 obesity trial, participants receiving 15 mg of tirzepatide lost approximately 21% of average body weight over more than 72 weeks, compared with approximately 3% for placebo. The treatment also improved waist circumference, blood pressure, and fasting insulin 25. Approximately 40% of participants had prediabetes at baseline, and more than 95% of those participants had normalized blood sugar levels by week 72 25. These results support a broad metabolic value proposition rather than a narrowly defined weight-loss benefit.
The head-to-head REIMAGINE-4 trial offers an important competitive signal. Novo Nordisk’s CagriSema, a combination of cagrilintide and semaglutide 1,38, achieved 15.2% weight loss at 68 weeks and met its prespecified non-inferiority margin against tirzepatide for weight reduction 7. CagriSema reduced HbA1c by 1.9 percentage points, compared with 2.2 percentage points for tirzepatide 7, and failed to meet the non-inferiority threshold for glycemic control 7,32. The distinction requires precision: the trial did not formally establish tirzepatide’s superiority on HbA1c; it established only that CagriSema failed to demonstrate non-inferiority 7. Even so, the result reinforces Lilly’s position in diabetes, where glycemic efficacy may be as important as weight reduction. The open-label design and full-adherence assumptions limit interpretation 7, so the findings should not be treated as an uncontested superiority result.
The commercial read-through is favorable, but not without contaminants. Demand is identified as a growth catalyst for Mounjaro 6, and Mounjaro coverage extends across diabetes and obesity indications outside the United States 26. At the same time, realized prices for relevant medicines declined 13% 28, with Mounjaro’s inclusion in China’s state-run insurance coverage cited as one contributor to lower non-U.S. prices 27. Volume growth may therefore remain strong while net pricing becomes a more material constraint.
Pipeline Differentiation: Retatrutide Raises the Competitive Bar
Retatrutide is Lilly’s most consequential next-generation obesity asset. It is a triple agonist targeting GLP-1, GIP, and glucagon, rather than the inaccurate “GLP-3” nickname 25,30. This mechanistic distinction could support greater weight loss and potentially broader metabolic effects than dual agonists such as tirzepatide 25,30.
The early efficacy signals are compelling. A phase 2 study reported approximately 24% average weight loss over more than 48 weeks, versus approximately 2% for placebo 25. In the TRIUMPH-1 program, average weight loss reached up to approximately 28% over 80 weeks in a study of more than 2,300 participants 25. TRIUMPH-4 reported approximately 29% average weight loss at the highest 12 mg dose over 68 weeks among adults with obesity and knee osteoarthritis; many participants also reported reduced knee pain 25. The broader TRIUMPH program has examined weight loss alongside A1C, cardiovascular risk factors, osteoarthritis pain, and sleep apnea 35.
These findings are promising, but cross-trial comparisons with tirzepatide remain provisional. The available evidence is insufficient to determine whether retatrutide is definitively more effective than Zepbound 4,27,28, even though early results may indicate a greater weight-loss benefit 34. Retatrutide is not available outside clinical trials 2,25,27,30, and its benefits remain unestablished pending completion of development 22,24,25,28,30,35. A potential FDA filing has been associated with early 2027, conditional on trial outcomes and completion of the CMC package 3,19,25,27,28,29,30,37.
The development timeline itself requires careful diligence. Some reports describe Phase 3 as completed and anticipate a regulatory application in the first quarter of 2027 31,34. Other, more cautious claims state that the TRIUMPH program remains ongoing, with Phase 3 data pending and TRIUMPH-5 still running 25,31. TRIUMPH-5 is described as a head-to-head trial against tirzepatide, with completion estimated for December 2026 and no early outcomes released as of July 19,21,30,33. Early-2027 filing expectations should therefore be treated as a contingent milestone, not a firm catalyst. The upside depends on confirmatory efficacy, safety, manufacturing, regulatory review, and the outcome of direct comparison with Lilly’s own incumbent product.
Formulation and Convenience: Oral Therapy Expands the Market
The market is moving beyond weekly injections. The first oral small-molecule GLP-1 pills were recently cleared by the FDA 11, and Lilly’s orforglipron, branded Foundayo, is a once-daily oral GLP-1 therapy 13,23,30. It is intended for weight management and type 2 diabetes. The United Kingdom was described as the first European country to approve it for those indications 12, while regulatory reviews were underway in the European Union, Japan, and Canada 23. NICE is expected to conduct a benefit-cost review before determining whether the UK public healthcare system should recommend the product 23. Until that review is complete, UK access may depend on private out-of-pocket payment 23.
The convenience profile is strategically attractive, but Foundayo’s initial commercial trajectory appears mixed. Weekly prescriptions remained flat for several weeks after the April launch and lagged the launch path of Novo Nordisk’s oral Wegovy 31. This contrasts with Novo’s claim that oral Wegovy launched at a record-breaking pace and had accumulated more than five million U.S. prescriptions 22,23,32. Different measurement periods, products, or definitions of launch success may explain part of the apparent contradiction. The broader lesson is more durable: oral availability alone does not guarantee rapid adoption. Lilly must establish a favorable balance of efficacy, tolerability, price, coverage, and prescribing familiarity.
Oral therapy may nevertheless be commercially sufficient even if its efficacy does not match the most powerful injectable regimens. An experimental oral GLP-1 pill produced up to 12.1% average weight loss in a 230-patient, 36-week trial, with nausea reported as an adverse event 14. In another comparison, orforglipron was associated with 11.2% average weight loss among participants sleeping at least eight hours, versus 8.9% for semaglutide in comparable adherence cohorts 20. These single-source observations are less robust than the multi-source tirzepatide evidence and should not be interpreted as a direct pivotal-trial comparison. They do, however, support the possibility that oral products can compete through convenience and adherence even when their efficacy is below that of injectable or triple-agonist candidates.
Manufacturing Capacity and Competitive Landscape
The manufacturing process reveals much about the durability of Lilly’s position. The company currently combines the commercial scale of tirzepatide, the potential efficacy advantage of retatrutide, and an oral option in orforglipron. That three-tiered portfolio offers multiple formulations for different patient preferences and clinical needs. It also creates a demanding manufacturing sequence: Lilly must sustain supply for an established injectable franchise while preparing the capacity, quality systems, and CMC package required for future products. Retatrutide’s potential filing remains conditional on completion of that CMC work 3,19,25,27,28,29,30,37.
Competition is intensifying across both obesity and diabetes 28. Amgen is advancing MariTide through Phase 3 39, with a potentially differentiated profile involving monthly or less frequent administration rather than daily or weekly dosing 39. Its commercial success remains conditional on favorable clinical outcomes 39, but a successful long-acting product could compete on adherence and convenience even without clearly superior weight-loss efficacy.
Regeneron is developing the dual GLP-1/GIP agonist olatorepatide, licensed from a China-based company 39. Phase 3 studies in China reportedly produced mean weight loss of up to 19% over 48 weeks 39, although cross-trial comparisons make its effectiveness relative to tirzepatide uncertain 39. Viking plans to advance VK2735 into Phase 3 in the fourth quarter of 2026, while Structure intends to initiate a late-stage aleniglipron trial in the second half of the year 31. The market is consequently fragmenting across efficacy, dosing frequency, oral convenience, and mechanism.
Indirect competition also deserves attention. Regeneron is developing a medicine intended to help preserve muscle mass during GLP-1-associated weight loss 39, an important consideration because patients can lose lean mass as well as fat mass 39. In the SURMOUNT-1 analysis, approximately 74% of tirzepatide-driven weight loss came from fat mass and 26% from lean mass; the analysis stated that lean-mass loss was not disproportionate 25. The issue could become more important as prescribers and payors emphasize body composition, physical function, and long-term outcomes.
Several claims suggest that sleep quality, obstructive sleep apnea treatment, diet, and exercise may influence GLP-1 outcomes 20,25. These observations are based largely on isolated sources and should be treated as hypothesis-generating rather than established evidence. If validated, they could expand tirzepatide’s value proposition and support integrated obesity-care models. They could also shift differentiation away from the medicine alone toward broader patient-management platforms.
Pharmacoeconomics, Access, and Risk
Reimbursement will determine how much of the clinical opportunity becomes realized revenue. The Medicare GLP-1 Bridge Program began expanding obesity-drug coverage in early July 2026 27. Eligible seniors can reportedly access selected branded GLP-1 medicines for a $50 monthly copay, including Lilly medicines distributed through Amazon Pharmacy 16,17,24,27. Early rollout data suggest that approximately 80% of patients used injectables and 60%–70% were new to therapy 35. This supports the view that reimbursement can unlock latent demand, although uptake under the program was initially uncertain 36. The federal Bridge price is scheduled to expire in 2027 5,15, making the post-program coverage and pricing environment material to Lilly’s U.S. growth and net price realization.
International markets present the same trade-off between access and price. U.S. drug prices are described as declining, although the magnitude is unspecified 10, while GLP-1 products can cost thousands of dollars per patient annually outside subsidized arrangements 18. China’s insurance inclusion of Mounjaro illustrates the formulation of the trade-off: coverage can accelerate patient access and volume while reducing realized prices 27. Lilly’s long-term earnings trajectory will depend on whether incremental patient volume more than offsets concessions to governments, insurers, and other institutional buyers.
Legal and safety narratives introduce additional uncertainty. Class-action petitions in Israel and Canada allege injuries related to incretin medicines including Mounjaro, Trulicity, and Zepbound 36. Another claim links more than 100 deaths to weight-loss medicines such as semaglutide and tirzepatide 9. These are isolated claims rather than corroborated findings in the supplied evidence and should not be treated as proof of product causality. They remain monitoring items because adverse-event publicity, label changes, or litigation could affect prescribing, payer policy, and the cost of risk management.
Investment Implications
Lilly enters the next phase of the GLP-1 market with an unusually strong scientific and commercial foundation. Tirzepatide’s momentum and its head-to-head glycemic result against CagriSema support continued competitive strength 7,8. The portfolio’s optionality is equally important: an established injectable franchise, a once-daily oral small molecule, and a potentially more potent triple agonist allow Lilly to address different patient preferences and therapeutic objectives.
The central question is whether Lilly can preserve premium economics as the market matures. Oral competition from Novo Nordisk’s Wegovy and Foundayo creates a convenience-led segment in which efficacy differentials may be less decisive. Monthly or less frequent therapies such as MariTide could disrupt the weekly-injection paradigm. Government coverage and negotiated pricing may expand the addressable market while compressing realized prices. The 13% decline in relevant realized prices is therefore an early warning that market growth should not be translated mechanically into revenue growth 28.
Retatrutide is the highest-impact pipeline variable. A successful launch could strengthen Lilly’s leadership and expand the premium end of obesity treatment, but it could also cannibalize part of the tirzepatide franchise. Conversely, disappointing Phase 3 results, safety findings, manufacturing delays, or a weaker-than-expected head-to-head showing against tirzepatide would remove a major source of future growth. Conflicting claims about whether Phase 3 is complete or ongoing make regulatory timing a near-term diligence item rather than a dependable forecast assumption 25,31,34.
The broader transition is from category creation to market structure. Demand should remain robust as reimbursement improves and global utilization rises, but returns will increasingly reflect product differentiation, payer negotiations, adherence, treatment persistence, and lifecycle management. Lilly’s advantage is strongest where clinical outcomes and manufacturing scale matter. Its vulnerabilities are greatest where oral convenience, dosing frequency, price, or regulatory access dominate.
What to Monitor
Investors should track prescription growth by product, net price trends, Medicare Bridge enrollment and post-2027 policy, retatrutide trial readouts, and the pace at which competitors advance differentiated formulations. These indicators will provide a more reliable assessment of durable competitive advantage than headline weight-loss percentages alone.
Bottom Line
- Tirzepatide is Lilly’s current anchor: Mounjaro and Zepbound have strong commercial momentum and challenged Novo Nordisk’s CagriSema on the glycemic endpoint, although REIMAGINE-4 was open-label and did not prove formal tirzepatide superiority 7.
- Retatrutide is the major upside catalyst but remains unapproved: Phase 2 and TRIUMPH results are highly promising, yet Phase 3 status and early-2027 filing timing are inconsistent across sources and require confirmation 25,31.
- The market is broadening while pricing pressure rises: Global patient growth and $50 Medicare access could expand volumes, while lower realized prices and the 2027 expiration of the Bridge pricing arrangement create earnings risk 5,15,27,28,31.
- Competitive diligence must extend beyond efficacy: Oral therapies, monthly dosing, muscle-preservation strategies, reimbursement, and payer access may determine market share as much as headline weight-loss percentages 13,23,39.